

Table 19.30
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2007-2013

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	99,036	69.6 (69.2 , 70.0)	89.9 (89.0 , 90.8)	76.0 (75.6 , 76.5)	59.1 (58.4 , 59.8)			
1 Hodgkin Lymphoma	8,117	85.6 (84.6 , 86.5)	96.3 (94.6 , 97.4)	88.8 (87.8 , 89.7)	56.6 (52.2 , 60.6)			
2 Non-Hodgkin lymphoma	88,734	68.6 (68.2 , 69.0)	88.4 (87.3 , 89.4)	74.6 (74.1 , 75.1)	59.7 (59.0 , 60.4)			
2(a) Non-Hodgkin lymphoma, B-cell	81,691	69.0 (68.5 , 69.4)	89.1 (87.9 , 90.2)	75.5 (75.0 , 76.0)	60.3 (59.5 , 61.1)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	4,401	68.3 (66.7 , 69.8)	88.3 (86.8 , 89.6)	38.4 (35.2 , 41.6)	17.4 (12.5 , 23.0)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	73,377	69.2 (68.7 , 69.7)	92.0 (89.6 , 93.9)	76.9 (76.4 , 77.5)	60.7 (59.9 , 61.5)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	19,315	78.2 (77.3 , 79.2)	- (- , -)	86.3 (85.2 , 87.3)	71.8 (70.3 , 73.2)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	16,568	81.7 (80.6 , 82.6)	- (- , -)	89.4 (88.2 , 90.4)	75.6 (74.0 , 77.1)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	63	52.9 (35.5 , 67.6)	- (- , -)	70.1 (44.5 , 85.6)	40.8 (20.3 , 60.3)			
2(a) 2.1.3. Mantle-cell lymphoma	2,684	57.3 (54.7 , 59.9)	- (- , -)	68.7 (65.2 , 71.9)	46.9 (42.9 , 50.8)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,680	80.6 (77.0 , 83.6)	- (- , -)	87.6 (83.3 , 90.9)	76.2 (71.0 , 80.6)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	732	77.5 (72.0 , 82.1)	- (- , -)	82.3 (75.1 , 87.7)	74.5 (66.5 , 80.9)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	948	83.0 (78.1 , 86.9)	- (- , -)	91.4 (85.4 , 95.0)	77.6 (70.3 , 83.2)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	18,768	62.3 (61.4 , 63.2)	91.2 (86.8 , 94.2)	69.9 (68.8 , 70.9)	52.5 (50.9 , 54.0)			
2(a) 2.3.1. DLBCL, NOS ^c	18,562	62.3 (61.3 , 63.2)	91.3 (86.8 , 94.3)	69.9 (68.9 , 71.0)	52.5 (51.0 , 54.1)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	28	35.8 (15.7 , 56.5)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.3. Primary effusion lymphoma	47	22.2 (9.1 , 38.8)	- (- , -)	18.4 (6.2 , 35.7)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	131	83.8 (73.3 , 90.4)	- (- , -)	85.1 (73.9 , 91.8)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	1,607	64.3 (61.6 , 66.9)	91.2 (87.5 , 93.8)	59.1 (55.7 , 62.3)	41.5 (32.9 , 49.9)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,449	89.1 (87.2 , 90.7)	100.0 (- , -)	92.2 (90.3 , 93.7)	85.4 (81.9 , 88.3)			
2(a) 2.5.1. Splenic MZL	386	85.4 (78.0 , 90.5)	- (- , -)	81.2 (72.1 , 87.6)	85.9 (77.0 , 91.6)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	2,649	94.0 (91.6 , 95.7)	100.0 (- , -)	95.3 (93.0 , 96.8)	92.2 (86.9 , 95.5)			
2(a) 2.5.3. Nodal MZL	1,414	80.6 (76.9 , 83.8)	- (- , -)	88.2 (84.2 , 91.2)	73.5 (67.5 , 78.6)			
2(a) 2.6. Follicular lymphoma	8,827	87.0 (85.8 , 88.1)	96.7 (77.2 , 99.6)	90.8 (89.6 , 91.8)	80.9 (78.5 , 83.2)			
2(a) 2.7. Hairy-cell leukemia	1,252	93.9 (91.0 , 95.9)	- (- , -)	96.4 (93.6 , 97.9)	86.4 (78.3 , 91.6)			
2(a) 2.8. Plasma cell neoplasms	17,461	49.5 (48.5 , 50.6)	- (- , -)	61.2 (59.8 , 62.6)	39.5 (38.0 , 40.9)			
2(a) 2.8.1. Plasmacytoma	1,199	68.5 (64.6 , 72.0)	- (- , -)	77.0 (72.6 , 80.7)	55.6 (48.3 , 62.3)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	16,262	48.1 (47.0 , 49.2)	- (- , -)	59.7 (58.2 , 61.1)	38.6 (37.1 , 40.1)			
2(a) 2.9. Heavy chain disease	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	3,913	66.2 (63.9 , 68.3)	92.9 (81.8 , 97.3)	73.5 (70.7 , 76.0)	59.8 (56.3 , 63.1)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.30 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2007-2013

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
2(b) Non-Hodgkin lymphoma, T-cell	6,454	64.4 (62.9 , 65.8)	86.6 (83.9 , 88.8)	66.5 (64.7 , 68.3)	50.0 (46.7 , 53.1)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	282	66.4 (60.4 , 71.7)	88.6 (82.0 , 92.9)	47.2 (37.9 , 56.0)	- (- , -)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	6,151	64.3 (62.7 , 65.8)	86.0 (83.0 , 88.6)	67.3 (65.4 , 69.1)	50.6 (47.3 , 53.8)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,472	88.3 (85.2 , 90.8)	100.0 (- , -)	90.8 (87.8 , 93.1)	81.6 (73.4 , 87.5)			
2(b) 2.1.1. Mycosis fungoides	1,422	90.1 (87.0 , 92.5)	100.0 (- , -)	91.9 (88.9 , 94.1)	85.1 (76.4 , 90.7)			
2(b) 2.1.2. Sezary syndrome	50	31.8 (13.4 , 51.9)	- (- , -)	- (- , -)	26.8 (5.3 , 55.5)			
2(b) 2.2. Peripheral T-cell lymphoma	3,330	56.1 (54.0 , 58.2)	82.9 (75.7 , 88.2)	62.8 (60.2 , 65.3)	42.4 (38.6 , 46.2)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	1,195	38.9 (35.5 , 42.4)	63.8 (41.9 , 79.3)	47.3 (42.7 , 51.7)	26.5 (21.4 , 31.9)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	411	35.8 (30.1 , 41.6)	- (- , -)	43.4 (34.9 , 51.5)	29.2 (21.3 , 37.5)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	30	87.0 (60.2 , 96.3)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	686	59.9 (55.5 , 64.1)	88.2 (79.7 , 93.3)	63.5 (58.1 , 68.4)	34.2 (24.6 , 44.0)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	38	21.8 (7.8 , 40.4)	- (- , -)	21.9 (5.6 , 45.0)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	32	12.6 (3.2 , 28.7)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	649	83.6 (78.9 , 87.4)	- (- , -)	86.9 (81.9 , 90.7)	76.6 (67.7 , 83.3)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	289	88.0 (80.6 , 92.7)	- (- , -)	93.8 (86.6 , 97.2)	78.2 (60.3 , 88.7)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	930	66.9 (63.2 , 70.3)	86.2 (82.5 , 89.2)	48.7 (42.2 , 54.8)	9.2 (1.1 , 28.6)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	296	42.9 (36.2 , 49.4)	- (- , -)	42.0 (34.3 , 49.4)	38.1 (23.6 , 52.5)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	31	62.8 (40.2 , 78.9)	- (- , -)	- (- , -)	- (- , -)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	92	17.9 (8.5 , 30.1)	- (- , -)	19.6 (8.3 , 34.3)	14.5 (2.9 , 35.0)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(c) Non-Hodgkin lymphoma, unknown lineage	589	56.1 (51.5 , 60.5)	83.3 (75.7 , 88.8)	53.4 (46.5 , 59.8)	40.6 (32.2 , 48.7)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	249	60.5 (53.8 , 66.5)	82.9 (75.2 , 88.5)	38.4 (26.5 , 50.1)	25.0 (11.9 , 40.5)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	321	53.0 (46.5 , 59.1)	- (- , -)	59.7 (51.3 , 67.1)	44.1 (34.0 , 53.7)			
2(*) 1. Total precursor lymphoma/leukemia ^d	4,932	67.9 (66.4 , 69.3)	88.1 (86.7 , 89.4)	39.5 (36.6 , 42.4)	17.9 (13.3 , 23.0)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	85	78.9 (65.2 , 87.6)	- (- , -)	81.3 (68.0 , 89.5)	- (- , -)			
4 Lymphoid neoplasm, NOS ^c	2,100	48.8 (46.0 , 51.4)	84.7 (72.2 , 91.9)	58.6 (54.9 , 62.2)	38.6 (34.6 , 42.6)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.